Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic|Breast Cancer
Interventions: DRUG: Olaparib|DRUG: Vorinostat
Sponsor: The Methodist Hospital Research Institute
Collaborators: AstraZeneca